

REMARKS / ARGUMENTS

In the above-identified Office Action the Examiner has rejected claims 1 and 2 as unpatentable over Kling et al. in view of Kumar et al. and further in view of Grace et al. In response, Applicant has amended the claims so that the integrin is now identified as $\alpha \beta_3$. Such integrin is not suggested or taught in the art of record and, accordingly, is patentable thereover.

Applicant hereby requests reconsideration and reexamination thereof.

No further fee or petition is believed to be necessary. However, should any further fee be needed, please charge our Deposit Account No. 23-0920, and deem this paper to be the required petition.

With the above amendments and remarks, this application is considered ready for allowance and applicant earnestly solicits an early notice of same. Should the Examiner be of the opinion that a telephone conference would expedite prosecution of the subject application, she is respectfully requested to call the undersigned at the below listed number.

Application No. 10/566,532
Amdt. dated 19 March 2009
Reply to Office Action of 23 December 2008

Respectfully submitted,



Dated: 19 March 2009

Gerald T. Shekleton
Reg. No. 27,466
Husch Blackwell Sanders Welsh & Katz
120 South Riverside Plaza, 22nd Floor
Chicago, Illinois 60606
Phone: (312) 655-1511
Fax: (312) 655-1501